Antithyroid Drug-Induced Aplastic Anemia

Thomas, D; Moisidis, A; Tsiakalos, A; Alexandraki, K; Syriou, V; Kaltsas, G

dc.contributor.author	Thomas, D	en
dc.contributor.author	Moisidis, A	en
dc.contributor.author	Tsiakalos, A	en
dc.contributor.author	Alexandraki, K	en
dc.contributor.author	Syriou, V	en
dc.contributor.author	Kaltsas, G	en
dc.date.accessioned	2014-03-01T01:57:18Z
dc.date.available	2014-03-01T01:57:18Z
dc.date.issued	2008	en
dc.identifier.issn	1050-7256	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/28397
dc.subject.classification	Endocrinology & Metabolism	en
dc.subject.other	COLONY-STIMULATING FACTOR	en
dc.subject.other	METHIMAZOLE-INDUCED AGRANULOCYTOSIS	en
dc.subject.other	BONE-MARROW APLASIA	en
dc.subject.other	GRAVES-DISEASE	en
dc.subject.other	PROPYLTHIOURACIL	en
dc.subject.other	RECOVERY	en
dc.subject.other	THERAPY	en
dc.subject.other	PLASMACYTOSIS	en
dc.subject.other	CSF	en
dc.title	Antithyroid Drug-Induced Aplastic Anemia	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	2008	en
heal.abstract	Background: Antithyroid drugs have been used for more than 50 years for the management of hyperthyroidism. Most patients tolerate treatment well but some may develop life threatening side effects such as agranulocytosis and aplastic anemia (AA). We review all cases of antithyroid drug induced AA and describe, as illustrative cases, two women with Graves' disease who developed AA after 8 and 24 weeks of carbimazole (CBM) and methimazole (MMI) treatment respectively. Patient findings and summary: To date, at least 34 cases of aplastic anemia (AA) due to antithyroid drugs [(1 with CMZ, 31 with MMI, and 2 with propylthiouracil (PTU)] have been published, not including the two patients described here. In addition, at least another 14 patients in whom AA developed after treatment with antithyroid drugs (11 with CMZ, and 3 with MMI) have been reported in Yellow Card Scheme data analysis. Patients with AA usually exhibit sudden onset of symptoms after a relative short time of exposure to the drugs, and all have concomitant agranulocytosis. Most have a rapid recovery following discontinuation of the drug and supportive treatment. Although only two antithyroid drug induced AA deaths have been published, the mortality rate was higher in the Yellow Card Scheme data analysis. Conclusions: Aplastic anemia associated with antithyroid drug treatment is rarer than antithyroid drug associated agranulocytosis. The prognosis of patients with antithyroid drug induced AA is good overall, but may not be as favorable as that of antithyroid drug induced isolated agranulocytosis.	en
heal.publisher	MARY ANN LIEBERT INC	en
heal.journalName	THYROID	en
dc.identifier.isi	ISI:000260247800003	en
dc.identifier.volume	18	en
dc.identifier.issue	10	en
dc.identifier.spage	1043	en
dc.identifier.epage	1048	en